Revah joins Genethon as ceo
Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.
Revah brings more than 20 years' experience in the pharmaceutical and biotech industries and academic research to the job.
Immediately prior to joining Genethon, Revah had been chief executive of the oncology start-up Sepal Pharma since 2008. Before that, he was vice president, Drug Discovery, and chief scientific officer of Cerep from 1999 to 2007 and chief executive of its oncology subsidiary.
